The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB
1
receptor, such as obesity, smoking cessation, and normalization of blood lipid composition.
[EN] T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE CANAUX CALCIQUES DE TYPE T ET LEURS MÉTHODES D'UTILISATION
申请人:PRAXIS PREC MEDICINES INC
公开号:WO2022099207A1
公开(公告)日:2022-05-12
The present invention is directed to, in part, deuterium-enriched compounds and compositions comprising a deuterium-enriched compound useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel.
Synthesis of deuterium-labeled crizotinib, a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)
作者:Wangwei Ao、Yuan Li、Yinsheng Zhang
DOI:10.1002/jlcr.3678
日期:2018.12
To more accurately and rapidly achieve quantitative detection of clinical crizotinib samples, stable isotopelabeled crizotinib was required as an internal standard. We have developed a method to prepare racemic [D9 ] crizotinib using a base-catalyzed H/D exchange of both nitroso compound 2 and the acetophenone compound 6 with D2 O and NaBD4 reduction of 7 as the key steps to introduce the 9 deuterium